CGRB Cougar Biotechnology (MM)

Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, at 2:15 p.m. EDT at the Millennium Broadway Hotel in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar�s current clinical development programs. Interested investors may access a live audio webcast and accompanying slide presentation by visiting the Investor Relations section of the Company�s Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days. About Cougar Biotechnology Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar�s oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase III clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types. Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.